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Abstract
Background:  Pseudomyxoma peritonei (PMP) is a rare malignant disease, most commonly
originating from appendiceal lesions and characterized by accumulation of mucinous tumor tissue
in the peritoneal cavity. Since the disease is infrequent, the task of carrying out studies of treatment
efficacy and disease biology in the clinical setting is challenging, warranting the development of
relevant in vitro and in vivo PMP models.
Methods: Human tumor tissue was implanted in the peritoneal cavity of nude mice to establish
two orthotopic models exhibiting noninvasive intraperitoneal growth without metastasis
development.
Results: Xenograft tissues have retained essential properties of the original human tumors, such
as macro- and microscopic growth patterns, mucin production as well as expression of
carcinoembryonal antigen, cytokeratins 20 and 7 and the proliferation marker pKi67. Upon
microscopic examination, the human tumors were categorized as the PMCA-I (peritoneal
mucinous carcinomatosis of intermediate features) subtype, which was conserved through 14
examined passages in mice, for the first time modeling this particular histopathologic category.
Conclusion: In conclusion, two novel orthotopic models of human PMP have been established
that consistently portray a distinct histopathologic subtype and reflect essential human tumor
properties. Xenografts can easily and reproducibly be transferred to new generations of mice with
acceptable passage periods, rendering the models as attractive tools for further studies of PMP
biology and treatment.
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Background
Pseudomyxoma peritonei (PMP) is a rare malignant dis-
ease characterized by progressive, abundant, multifocal
accumulation of mucinous tumor tissue in the peritoneal
cavity, essentially without extraperitoneal growth and
metastasis development. Patients usually present with
abdominal distension due to tumor growth as their main
symptom, and untreated, progressive growth over several
years will lead to abdominal compression and a fatal out-
come. The intraabdominal origin of PMP has been a con-
troversial issue, particularly versus borderline ovarian
tumors. Consensus now, however, based on immunohis-
tochemical and molecular studies, is that PMP is of intes-
tinal origin, most commonly originating from
appendiceal lesions [1-5].
Cytoreductive surgery, which ideally includes complete
removal of all macroscopic lesions, remains the corner-
stone of treatment for PMP, and the extent of cytoreduc-
tion has been reported to have an impact on disease
survival [6,7]. Surgery has during the latter decades been
supplemented by intraperitoneal chemotherapy, most
commonly in the form of hyperthermic intraperitoneal
chemotherapy (HIPEC) using Mitomycin C. HIPEC has
been implemented as standard therapy in many treatment
centers, although its superiority to surgery alone has not
been assessed in randomized controlled trials. The addi-
tion of HIPEC increases treatment morbidity and mortal-
ity, thus warranting careful patient selection and
continuous assessment of potential factors to enable pre-
diction of prognosis based on pretreatment information.
Three histopathological subtypes were identified in a
series of 109 PMP patients receiving cytoreductive surgery
and intraperitoneal chemotherapy: disseminated perito-
neal adenomucinosis (DPAM), peritoneal mucinous car-
cinomatosis (PMCA) and an intermediate histological
type (PMCA-I/D) [8]. Patients with DPAM had 5- and 10-
year survival rates of 75% and 68%, respectively, whereas
corresponding survival rates for PMCA-I/D were 50% and
21%, and for PMCA 14% and 3%. Similar results were
recently reported in two different patient populations
[9,10], and the importance of histological classification as
one of few predictive prognostic variables in PMP was fur-
ther substantiated by an alternative, dichotomous classifi-
cation system [11], additionally emphasizing an
unresolved controversy in PMP, namely one of nomencla-
ture.
Studies of PMP biology and evaluation of different treat-
ment regimens have been hampered by the lack of appro-
priate in vitro and in vivo models, leaving researchers to
draw conclusions from clinical studies only, with the
obvious limitations this confers in such a rare condition.
Animal models of PMP should mimic the peritoneal
growth pattern and lack of metastasis development and
also reflect histopathological classification. Since stand-
ard treatment of PMP is essentially local, involving surgery
and intraperitoneal chemotherapy, tumor models should
be orthotopic, that is, established as intraperitoneal (i.p.)
rather than subcutaneous (s.c.) xenografts. To our knowl-
edge, no models have so far been described to complete
these criteria. The present report describes the establish-
ment and characterization of two novel orthotopic
xenograft models in mice from human PMP tissue.
Methods
Patients
Tumor tissue was acquired from arbitrarily selected tumor
areas from patients undergoing surgical treatment for
pseudomyxoma peritonei at The Norwegian Radium Hos-
pital, after obtaining written informed consent. The study
was approved by the Regional Committee for Medical
Research Ethics of Southern Norway. No chemotherapy
was given to any of the patients prior to the main surgical
procedure.
Patient 1:
The surgical specimen used to establish the PMP-1 model
was obtained from an 83-year-old woman whose primary
surgery had taken place 6 years previously when an iso-
lated appendiceal mucinous cystadenoma was removed
by ileocecal resection. She presented with abdominal dis-
tension and a preoperative CT scan indicated multiple,
large tumor foci throughout the abdominal cavity, upon
which palliative surgical removal of large amounts of
abdominal mucinous tumor tissue was performed.
Patient 2:
Tissue for the PMP-2 model was collected from a dissem-
inated abdominal mucinous tumor in a 56-year-old
woman. She had been subjected to two previous surgical
procedures, the first eight years previously when resection
of a mucinous adenocarcinoma of the appendix with a
metastatic lesion to the right ovary was performed, and
the second two years later when the left ovary with a muci-
nous cystadenomatous tumor was removed, consistent
with a metastatic lesion. The patient experienced abdom-
inal swelling and CT scans indicated a disseminated
tumor recurrence. A curative surgical strategy was pursued,
including removal of the omentum majus, resection of
the transverse colon, splenectomy, cholecystectomy and
pelvic peritonectomy.
Animals
Locally bred female BALB/c nude (nu/nu) mice, 6–8
weeks of age at implantation, were used. The animals were
maintained under specific pathogen-free conditions, and
food and water were supplied ad libitum. Housing and allBMC Cancer 2007, 7:116 http://www.biomedcentral.com/1471-2407/7/116
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procedures involving animals were performed according
to protocols approved by the animal care and use commit-
tee, in compliance with the National Committee for Ani-
mal Experiments guidelines on animal welfare. During
surgical procedures, mice were anaesthetized using s.c.
injections of 0.075 ml/10 g of a mixture of tiletamine, 2.4
mg/ml and zolazepam, 2.4 mg/ml, (Zoletil vet, Virbac
Laboratories, Carros, France), xylazine, 3.8 mg/ml, (Nar-
coxyl vet, Roche, Basel, Switzerland) and butorphanol,
0.1 mg/ml, (Torbugesic, Fort Dodge Laboratories, Fort
Dodge, Iowa, USA).
Tumor models
Fresh tumor tissue was cut into 3 × 3 × 3 mm pieces and
implanted either s.c. or i.p. For i.p. implantation a small
midline laparotomy was performed and six tumor pieces
placed in the peritoneal cavity in both upper and lower
abdominal quadrants as well as in both flanks. After
implantation, the abdominal wall was closed in two lay-
ers with Dexon 5/0. In later i.p. passages, mucinous ascites
dominated the growth pattern, and transfer of tissue was
in such cases alternatively performed by i.p. injection of
250  µl of mucinous ascites, and no laparotomy was
required. Usually, 2–3 mice were implanted or injected
per passage.
Sampling and evaluation
The well being of the mice was carefully monitored and
animals were sacrificed when and if signs of disease were
detected. In i.p. implanted mice, the main indicator of
tumor growth proved to be increased abdominal volume,
and if no other symptoms were present they were sacri-
ficed when a distinct increase of abdominal size was
detectable, typically 1–3 months after implantation. In
s.c. implanted mice, tumors were allowed to reach a max-
imum of 20 mm in longest diameter provided that the
animal had no symptoms from the tumor. Autopsy was
performed and macroscopic assessment was made for the
presence of tumor tissue or metastatic lesions and sam-
pled for further analyses.
Histological examination and immunohistochemical 
staining
Formalin fixed tissue from primary lesions, main surgical
specimens as well as samples from all tumor-bearing mice
were subjected to haematoxylin-eosin (HE) and alcian
blue staining using standard protocols. Histological clas-
sification was performed according to Ronnett et al [8].
Additionally, selected samples from each passage through
passage 6 were immunostained using monoclonal anti-
bodies against carcinoembryonal antigen (CEA), cytoker-
atin 7 (CK7), cytokeratin 20 (CK20) and Ki67 (Table 1)
using the Dako EnVision™ + detection system according to
manual (DAKO, Glostrup, Denmark). For all antibodies,
positive controls were included with satisfactory results.
The number of immunoreactive tumor cells was semi
quantitatively evaluated: 0 (no positive cells), <10%, 10–
50%, >50%, 100%. Positive staining for CEA, CK7 and
CK20 was noted as cytoplasmic or membranous and for
Ki67 nuclear staining was assessed. As these lesions often
are paucicellular, immunohistochemistry was performed
on sections from the block with the most cellular tumor
tissue, and the entire section was then evaluated to estab-
lish an immunoreactive score.
Results
Tumor growth in animal models
The typical initial i.p. growth pattern was characterized by
mucinous ascites accompanied by a variable number of
"solid" mucinous tumor lesions of varying size (Figure 1).
The solid tumor components were attached to the perito-
neum and the serosa of intraperitoneal organs, such as
urinary bladder, omentum majus, ovaries, liver- and
splenic hilum, but invasive growth was never observed in
HE sections. No metastatic lesions were observed in any
animal throughout the entire series. After several passages,
the growth pattern in both models changed to be increas-
ingly dominated by mucinous ascites with less frequent
appearance of lesions adhering to abdominal organs.
From passage 6, parallel grafting was performed by injec-
tion of mucinous ascites, and this mode of passage
resulted in some reduction of the time period between
grafting and discernible abdominal distension. The take
rate was close to 100% regardless of subculturing strategy,
but with the injection approach, tumor growth was more
synchronized within each generation. Using the injection
approach, we have also succeeded in reestablishing i.p.
growth from harvested material that has been stored at -
196°C for 3–6 months. We were unable to establish s.c.
growth for the PMP-2 model, but PMP-1 did grow when
Table 1: Primary antibodies and immunostaining conditions used for immunohistochemical studies in primary tumors, main surgical 
specimens and xenografts.
Antibodies Catalogue Pretreatment Dilution Positive controls
CEA Dako M7072 Low pH 1/100 Intestinal mucosa Colon cancer
CK20 Progen 61026 Tris-EDTA 1/100 Intestinal mucosa Colon cancer
CK7 Dako M7018 Tris-EDTA 1/200 Intestinal mucosa Colon cancer
Ki67 Dako M7240 Tris-EDTA 1/150 AppendixBMC Cancer 2007, 7:116 http://www.biomedcentral.com/1471-2407/7/116
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implanted s.c., although more slowly than in the i.p. loca-
tion. Thus, the s.c. xenografts have presently reached pas-
sage 5, whereas both i.p. models are in passage 14. In HE
and alcian blue stained sections, tumor tissue harvested
from the s.c. location did not differ from the i.p. counter-
parts, and results from the PMP-1 s.c. model will not be
presented in further detail.
Microscopic assessment
The primary lesion of patient 1 was an appendiceal muci-
nous cystadenoma with low grade atypia, whereas the
patient 2 primary lesion had the characteristics of a muci-
nous adenocarcinoma. The peritoneal lesions from the
two main surgical specimens were, however, remarkably
similar upon microscopic examination (Figure 2). The
tumors were dominated by extracellular mucin with strips
of bland, adenomatous, mucinous epithelium, but focal
areas were observed, exhibiting more abundant, glandular
epithelium with nuclear stratification, rendering the
microscopic picture slightly more "aggressive" than
DPAM and consistent with the PMCA-I category. No
parenchymal infiltration or signet ring cells were
observed, hardly any mitoses were seen and atypia was
minimal. The histological picture observed in xenografts
from both models was almost identical to the original
human tumors, consistently portraying the PMCA-I histo-
logical subgroup, although the general impression was
that the xenografts were slightly richer in epithelial cells
(Figure 2, panels D and H). All examined tumors were
shown to contain intra- and extracellular mucin visual-
ized by Alcian blue staining on sections from selected pas-
sages (Figure 3E).
Immunohistochemistry (Table 2 and Figure 3)
The two intestinal tumor markers, CEA and CK20, were
highly expressed in both primary tumors, main surgical
specimens and in all specimens harvested from the first six
animal passages, with membranous and cytoplasmic
staining observed in 100% of tumor cells in all but one
section. CK7, a cytokeratin commonly associated with
gynecological malignancies, was essentially not detectable
in the PMP-1 model, with the exception of slight membra-
nous staining in two of the murine passages (<10% of
tumor cells). In contrast, PMP-2 exhibited high expression
of this cytokeratin in all examined specimens, with pre-
dominantly membranous staining observed in the
xenografts, whereas the human equivalents displayed
combined cytoplasmic and membranous staining.
Nuclear presence of the proliferation marker pKi67 was
Microscopic growth assessed by HE staining Figure 2
Microscopic growth assessed by HE staining. Top pan-
els (A, B, C and D) and bottom panels (E, F, G and H) repre-
sent sections from the PMP-1 and PMP-2 models, 
respectively. In both patients, primary tumor manifestations 
were appendiceal lesions; (A) Patient 1: cystadenoma of the 
appendix with low grade atypia. (E) Patient 2: mucinous aden-
ocarcinoma, the selected section illustrating an area of inva-
sive growth in the appendiceal wall. Peritoneal lesions from 
the main surgical specimens were remarkably similar in the 
two patients, exhibiting focal areas of cribriform growth and 
nuclear stratification (B and F), but in both cases, the his-
topathologic picture was dominated by strips of bland epithe-
lium lining large accumulations of extracellular mucin (C and 
G). In xenografts from both models a similar histological 
growth pattern was observed, with adenomucinosis as the 
dominating manifestation, but with focal areas of nuclear 
stratification and cribriform growth, leading to classification 
as PMCA-I (D and H).
Autopsy photographs illustrating macroscopic growth pat- terns in tumor models Figure 1
Autopsy photographs illustrating macroscopic 
growth patterns in tumor models. A) In passage 4 of 
PMP-1 some non-adherent mucinous ascites was observed , 
but adherent tumor tissue dominated the picture with tumor 
lesions identified on the surface of the urinary bladder, liver 
hilum and mesentery of the small intestine. B) Passage 0 of 
the PMP-2 model exhibited almost exclusively large, "solid" 
tumors adherent to intraperitoneal surfaces such as liver 
hilum, retroperitoneum and urinary bladder.BMC Cancer 2007, 7:116 http://www.biomedcentral.com/1471-2407/7/116
Page 5 of 7
(page number not for citation purposes)
detected in 10–50% of cells in the PMP-1 primary tumor
and main surgical specimen, and this feature was con-
served throughout the animal passages. In the PMP-2
model, the pKi67 expression was less consistent, with low
and intermediate Ki67 positive cell fractions in the pri-
mary tumor and main surgical specimen, respectively,
whereas positive fraction in tumor tissue from the animals
was consistently high (>50%).
Discussion
Human tumor tissue from two patients with PMP was suc-
cessfully implanted into the peritoneal cavity of nude
mice to establish two novel, orthotopic animal models.
Xenografts have retained fundamental properties of the
implanted specimens through several passages, harboring
strict peritoneal, noninvasive growth, absence of metas-
tases, and almost identical morphologic appearance of
tumor tissue and immunohistochemical staining pat-
terns.
The macroscopic growth pattern of the models closely
resembled their human counterparts, as tumor expansion
in the i.p. site was characterized by strict peritoneal
growth without invasion of peritoneal surfaces and no
metastasis development. Also, much like patients afflicted
with PMP, the condition was asymptomatic in the mice,
to be detected only by increasing abdominal distension.
An interesting difference between murine and human
tumors was the xenograft tendency to grow as unattached,
mucinous ascites, whereas the tissue harvested from the
respective patients was rather fibrous in consistency and
more firmly adherent to intraabdominal peritoneal sur-
faces, although without invasive growth. There is no obvi-
ous explanation for this observation; however, since
microscopic assessment and immunohistochemical anal-
ysis revealed almost identical findings in human and
xenograft tissues, essential phenotypes of the human
tumors seem to have been conserved. For practical pur-
poses, this property has been quite useful, since regrafting
by injection of mucinous ascites has eliminated the need
for laparotomy, sparing the mice from surgical trauma
and being less time consuming. If large series were to be
attempted, for instance to test efficacy of chemotherapeu-
tic agents, this might constitute a great advantage.
Histological assessment, comparing tissue architecture,
cell morphology and mucin distribution showed convinc-
ing similarity between implanted patient tissue and har-
vested xenografts. Although the primary lesion in the
PMP-2 patient was diagnosed as a mucinous adenocarci-
noma and the PMP-1 primary lesion was non-invasive,
the resulting peritoneal manifestations of both main sur-
gical specimens displayed characteristics of PMCA-I, an
intermediary histologic category harboring mainly DPAM
features, but with focal areas containing more atypical
epithelium [8]. Although tumors from the animals were
slightly richer in epithelial cells, the PMCA-I picture was
representatively preserved in animal passages, for the first
time providing models specifically portraying this his-
topathological subtype.
A very limited number of studies have addressed pheno-
typic traits of PMP cells, and most of these have been
immunohistochemical studies focused on clarifying the
intra-abdominal origin of the disease. In this study,
immunohistochemical analyses were undertaken for two
main reasons, to compare expression patterns with previ-
ously published results and to see whether phenotypic
characteristics of implanted tissue would be conserved in
the models. CEA is widely used as a tumor marker in
colorectal cancer, and previous studies have shown that
serum levels are also often elevated in patients with PMP
[12]. Hence, the high expression of CEA in tumor cells in
human tumors and xenografts is not surprising. The uni-
formly high expression of CK20 is also in agreement with
Immunohistochemical and alcian blue staining of xenograft  tissues Figure 3
Immunohistochemical and alcian blue staining of 
xenograft tissues. Consistently high membranous and 
cytoplasmic expression of CEA and CK20 (panels A and B, 
respectively) was observed in primary tumors, main surgical 
specimens and in all specimens harvested from the first six 
animal passages, here illustrated by sections from PMP-1 pas-
sage 1. CK7, on the other hand was hardly expressed in the 
PMP-1 series (panel C), whereas the PMP-2 model (passage 
2) exhibited high expression of this cytokeratin (panel D), 
showing a distinct phenotypic difference between otherwise 
very similar tumors. Intra- and extracellular mucin was 
present in all examined sections (panel E). A high fraction of 
pKi67 positive cells was detected, and in this PMP-1 passage 
3 tumor 10–50% of tumor cell nuclei were stained (panel F).BMC Cancer 2007, 7:116 http://www.biomedcentral.com/1471-2407/7/116
Page 6 of 7
(page number not for citation purposes)
previously published results and with the appendiceal ori-
gin of PMP [1]. Implanted tissue in the PMP-1 model was
negative for CK7 expression and only slight (<10%) mem-
branous staining was seen in two of the murine passages,
whereas the PMP-2 model exhibited high membranous
CK7 expression in all examined sections. While this cytok-
eratin is more commonly associated with ovarian malig-
nancies, previous immunohistochemical studies have
shown that although tumors derived from the appendix
in general are negative for CK7; in some cases, appendi-
ceal adenomas and derived peritoneal lesions may be CK7
positive [1,2,13]. Taken together, the expression patterns
of CEA, CK20 and CK7 conform well to previous observa-
tions in PMP, and findings within each of the two models
were consistent throughout the examined passages.
The analysis of pKi67 expression is a well-established
method to determine the fraction of actively proliferating
cells in a tissue, and the fraction of Ki67 positive cells has
been suggested as a marker to predict both disease prog-
nosis and therapy response [14]. Since PMP lesions have
not been studied with respect to pKi67 expression,
assumptions about the expected frequency of positive
cells cannot be made a priori. Examined sections from sur-
gical specimens used for implantation exhibited in both
cases positive staining for pKi67 in 10–50% of cells, indi-
cating that these were indeed actively proliferating
tumors. In the PMP-1 model the fraction of pKi67-
expressing cells was almost identical in all murine pas-
sages, whereas PMP-2 xenografts exhibited higher scores
than the implanted tissue. The fairly high Ki67 score was
somewhat surprising considering that almost no mitotic
figures were identified in tumor epithelium in HE sec-
tions, but consistent with the clinical presentation in the
patients as well as with the observed rapid intraperitoneal
growth in mice.
Yakushiji et al were able to grow tissue from an ovarian
tumor both i.p. and s.c. in nude mice, and based on
microscopic appearance it was classified as "ovarian pseu-
domyxoma peritonei" [15]. Although no detailed his-
topathological description was provided, published
images certainly suggest the presence of mucinous tumor
tissue, and the described growth patterns, dependable
take rates and favored i.p. growth seem well in keeping
with our findings. Similar to our findings, mucinous
Table 2: Results of immunohistochemical staining performed on sections from the patients' primary tumors, the surgical specimens 
implanted in the animals as well as the first passages in the two animal models (p0 – p6).
CEA CK20 CK7 Ki 67
PMP-1 Primary tumor 100% m/c 100% m/c 0 10–50%
Main surgical specimen 100% m/c 100% m/c 0 10–50%
p0 100% m/c 100% m/c <10% m 10–50%
p1 100% m/c 100% m/c 0 >50%
p2 100% m/c 100% m/c 0 10–50%
p3 100% m/c 100% m/c 0 10–50%
p4 100% m/c 100% m/c 0 10–50%
p5 100% m/c 100% m/c 0 10–50%
p6 100% m/c 100% m/c <10% m 10–50%
PMP-2 Primary tumor >50% m/c 100% m/c 10–50% m/c <10%
Main surgical specimen 100% m/c 100% m/c 100% m/c 10–50%
p0 100% m/c 100% m/c 100% m/c >50%
p1 100% m/c 100% m/c 100% m >50%
p2 100%m/c 100% m/c 100% m >50%
p3 100% m/c 100% m/c 100% m/c >50%
p4 100% m/c 100% m/c >50% m 10–50%
p5 100% m/c 100% m/c 100% m >50%
p6 100% m/c 100% m/c 100% m >50%
Numbers indicate percentage of cells stained in the section.
m = membranous staining c = cytoplasmic staining
A consistently high expression was seen for CEA and CK20 in both tumors as well as in tumor tissue harvested from the animals. The PMP-1 model 
was essentially negative for CK7 expression, with the exception of slight membranous staining in two of the passages, whereas PMP-2 exhibited a 
relatively consistent, high expression of this cytokeratin. A Ki67 positive cell fraction of 10–50% in the primary tumor was conserved throughout 
the animal passages in the PMP-1 animal model. In the PMP-2 model, low and intermediate Ki67 positive cell fractions were found in the primary 
tumor and main surgical specimen, respectively, whereas in tissue harvested from the animals the positive fraction was consistently high (>50%).Publish with BioMed Central    and   every 
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deposits were reported to be positive for alcian blue stain-
ing, and serum levels of CEA were elevated in tumor bear-
ing mice compared to control mice, indicating relevance
of CEA in this model as well. Interestingly, the authors
also succeeded in utilizing the model to assess the effect of
i.p. injections of cisplatin and adriamycin on tumor
growth, thus confirming the usefulness of this strategy for
in vivo studies of i.p. chemotherapeutic efficacy.
Conclusion
Two novel orthotopic models of human PMP were estab-
lished in mice, in which macroscopic growth pattern, the
specific histopathologic subtype and immunohistochem-
ical expression pattern of the implanted material were
well preserved. Xenograft material can easily and repro-
ducibly be transferred to new generations of mice with
acceptable passage periods, rendering the models as
attractive tools for further studies of PMP biology and
treatment.
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